Biomics Biotechnologies Co., Ltd.

Biomics Biotechnologies Co., Ltd. was established by a group of overseas returnees under the leadership of Dr. Zhu Yuanyuan in 2006. It has a registered capital of ＄12.12 million and a total investment of ＄25 million, It is mainly engaged in the development of small nucleic acid drugs and the industrialization of products. The Company is spread over an area of 100 mu (6.6 hectares) industrial land where there is the first stage construction of an international research and development and production base for small nucleic acid drugs. Equipped with first-class production and development technology and equipment, it has become the leading enterprise in the domestic small nucleic acid drug industry.

Currently, the Company has nine overseas experts. Among 100 employees, 11 of them have a doctor’s degree, 12 have master’s degrees and 78 percent of the staff are professionals. The Company boasts a complete technology platform for the development of small nucleic acid drugs, including library synthesis of small nucleic acids. It has become an index enterprise in terms of the development of nucleic acid drugs and industrialization of products.

After five years’ development, the Company has made impressive achievements. 32 domestic and foreign patents were won, including seven American patents and two PCT patents. Some independent innovations and intellectual property rights in small nucleic acid drugs research on the treatment of age-related macular degeneration (AMD), liver cancer, hepatitis B, bladder cancer, nasopharyngeal carcinoma and other diseases have reached international advanced levels in some respects and filled gaps in the same industry. As a subsidiary of Biomics Biotechnologies Co., Ltd, Jiangsu GeneCon Biotechnologies Co., Ltd. is taking the lead in the introduction of the world's first small nucleic acid health products for civil use, filling in the blanks at home and abroad.

The Biomics-GeneCon Company has been marked as the "incubator base of small nucleotides drugs" by the Ministry of Science and Technology for significant new drug development of the Twelfth National Five-Year Plan in 2010. In 2011, the incubator base of small nucleotides drugs (Biomics-GeneCon) obtained national funding of 86,505 million yuan for its Engineering Center. Meanwhile, the Engineering Technology Research Center of Small Nucleotide Drugs has been identified as a provincial engineering technology center in Jiangsu province.